Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
Conclusions: In this multi-institutional case series, single-agent ICI demonstrated objective responses and was well tolerated in a heterogeneous treatment-naïve mRCC cohort. ICI monotherapy is not the standard of care for patients with mRCC, and further investigation is necessary to explore predictive biomarkers for optimal treatment selection in this setting.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Accidents | Cancer & Oncology | Carcinoma | Clinical Trials | Clostridium Difficile | Dermatitis | Dermatology | Hepatocellular Carcinoma | Kidney Cancer | Liver | Liver Cancer | Renal Cell Carcinoma | Statistics | Translocation | Urology & Nephrology | USA Health